drugset / Trial / NCT00299962
Gene Therapy for Pleural Malignancies
Phase 1
Completed
17 enrolled
University of Pennsylvania
Biogen · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: * malignant pleural mesothelioma, or * pleural effusions who have progressed through at least one prior therapy or have refused therapy BG00001 is given twice through a catheter in the pleural space.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-05
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG00001 | Unknown | 1.5e+12 vg | Other |
| Subject | BG00001 | Unknown | 3e+12 vg | Other |